Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Kneebone

Showing results (91-100 of 124) with videos related to

Pageof 13
Sort By:
Leukemia & Lymphoma|February 15, 2011
Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology GroupAndrew Wirth, Andrew Grigg, Max Wolf, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 2008
3D radiotherapy can be safely combined with sandwich systemic gemcitabine chemotherapy in the management of pancreatic cancer: factors influencing outcomeNigel Spry, Jennifer Harvey, Craig Macleod, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 28, 2017
Treatment Outcomes from <sup>68</sup>Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PETLouise Emmett, Pim J van Leeuwen, Rohan Nandurkar, et al.
Medical Physics|January 8, 2015
The first clinical treatment with kilovoltage intrafraction monitoring (KIM): a real-time image guidance methodPaul J Keall, Jin Aun Ng, Ricky O'Brien, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 10, 2019
Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary groupHester Lieng, Andrew Kneebone, Amy J Hayden, et al.
BJU International|April 29, 2022
Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groupsMatthew J Roberts, Mark D Chatfield, George Hruby, et al.
International Journal of Radiation Oncology, Biology, Physics|October 31, 2007
Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomyKirsty L Wiltshire, Kristy K Brock, Masoom A Haider, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 25, 2017
The Impact of <sup>68</sup>Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter StudyPaul J Roach, Roslyn Francis, Louise Emmett, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 25, 2018
Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary groupHester Lieng, Amy J Hayden, David R H Christie, et al.
Frontiers in Oncology|October 4, 2021
Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical ReviewByeongsang Oh, Frances Boyle, Nick Pavlakis, et al.
Pageof 13

Showing results (91-100 of 124) with videos related to

Sort By:
Pageof 13
Leukemia & Lymphoma|February 15, 2011
Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology GroupAndrew Wirth, Andrew Grigg, Max Wolf, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 2008
3D radiotherapy can be safely combined with sandwich systemic gemcitabine chemotherapy in the management of pancreatic cancer: factors influencing outcomeNigel Spry, Jennifer Harvey, Craig Macleod, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 28, 2017
Treatment Outcomes from <sup>68</sup>Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PETLouise Emmett, Pim J van Leeuwen, Rohan Nandurkar, et al.
Medical Physics|January 8, 2015
The first clinical treatment with kilovoltage intrafraction monitoring (KIM): a real-time image guidance methodPaul J Keall, Jin Aun Ng, Ricky O'Brien, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 10, 2019
Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary groupHester Lieng, Andrew Kneebone, Amy J Hayden, et al.
BJU International|April 29, 2022
Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groupsMatthew J Roberts, Mark D Chatfield, George Hruby, et al.
International Journal of Radiation Oncology, Biology, Physics|October 31, 2007
Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomyKirsty L Wiltshire, Kristy K Brock, Masoom A Haider, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 25, 2017
The Impact of <sup>68</sup>Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter StudyPaul J Roach, Roslyn Francis, Louise Emmett, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 25, 2018
Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary groupHester Lieng, Amy J Hayden, David R H Christie, et al.
Frontiers in Oncology|October 4, 2021
Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical ReviewByeongsang Oh, Frances Boyle, Nick Pavlakis, et al.
Pageof 13